{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hong KT"],"funding":["Ministry of Food and Drug Safety"],"pagination":["48"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11934747"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Background</h4>Post-transplantation cyclophosphamide (PTCy) has paved the way for the increased use of alternative donors, including haploidentical familial donors, with acceptable engraftment and graft-versus-host disease (GVHD) rates. However, pharmacokinetic studies of PTCy in the pediatric population following myeloablative conditioning regimens are scarce.<h4>Methods</h4>We conducted a prospective and comprehensive pharmacokinetic analysis of pre- and post-transplantation cyclophosphamide levels in pediatric patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) using a myeloablative busulfan-based conditioning regimen. A total of 14 samples were collected from each patient. Plasma concentrations of cyclophosphamide and carboxycyclophosphamide were analy"],"journal":["Biomarker research"],"pubmed_title":["Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation."],"pmcid":["PMC11934747"],"funding_grant_id":["21184MFDS286"],"pubmed_authors":["Hong KT","Sunwoo Y","Cho JY","Choi JY","Kang HJ","Bae S","Oh J","Yu KS","Lee J","Park HJ","Kim BK"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation.","description":"<h4>Background</h4>Post-transplantation cyclophosphamide (PTCy) has paved the way for the increased use of alternative donors, including haploidentical familial donors, with acceptable engraftment and graft-versus-host disease (GVHD) rates. However, pharmacokinetic studies of PTCy in the pediatric population following myeloablative conditioning regimens are scarce.<h4>Methods</h4>We conducted a prospective and comprehensive pharmacokinetic analysis of pre- and post-transplantation cyclophosphamide levels in pediatric patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) using a myeloablative busulfan-based conditioning regimen. A total of 14 samples were collected from each patient. Plasma concentrations of cyclophosphamide and carboxycyclophosphamide were analy","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-06-25T03:04:12.977Z","creation":"2025-06-25T03:04:12.977Z"},"accession":"S-EPMC11934747","cross_references":{"pubmed":["40128919"],"doi":["10.1186/s40364-025-00749-3"]}}